Disparities in Early Lecanemab Uptake Among US Medicare Beneficiaries

Frank F Zhou; Utibe R Essien; Jeffrey M Souza; Catherine A Sarkisian; Cheryl L Damberg; Bruce E Landon; John N Mafi

doi:10.1001/jamanetworkopen.2025.11711

Disparities in Early Lecanemab Uptake Among US Medicare Beneficiaries

JAMA Netw Open. 2025 May 1;8(5):e2511711. doi: 10.1001/jamanetworkopen.2025.11711.

Authors

Frank F Zhou¹, Utibe R Essien¹, Jeffrey M Souza^{2

3}, Catherine A Sarkisian^{1

4}, Cheryl L Damberg⁵, Bruce E Landon^{2

3}, John N Mafi¹

Affiliations

¹ Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at UCLA, University of California, Los Angeles.
² Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts.
³ Division of General Internal Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
⁴ Geriatric Research Education and Clinical Center (GRECC), Veterans Association Greater Los Angeles Healthcare System, Los Angeles, California.
⁵ RAND Health, RAND, Santa Monica, California.

No abstract available

Plain language summary

This cross-sectional study examines lecanemeb update among Medicare fee-for-service beneficiaries with Alzheimer disease or mild cognitive impairment and evaluates whether there are disparities among potentially eligible patients.